Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab in Locally Advanced Oral Cancer
NCT03843515Phase 1Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2019
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in oral cavity squamous cell carcinoma (OCSCC), sponsored by Amsterdam University Medical Center. Primary endpoints: Incidence of (Serious) Adverse Events and Standardized Uptake Value (SUV) from PET Imaging at 2 years. Status: unknown.
02
Drugs
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT03843515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843515.